15/03/2026
The article "Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration” discusses the potential anticancer effects of fenbendazole, a veterinary antiparasitic drug. The report describes three patients with advanced cancers—breast cancer, prostate cancer, and melanoma—who used fenbendazole as part of their treatment regimen alongside other therapies (excluding chemotherapy). According to the case series, two patients experienced complete remission and one achieved near-complete remission after incorporating fenbendazole into their treatment approach. The patients reportedly tolerated the drug well, with no significant adverse effects observed during treatment.
The study highlights that fenbendazole may have anticancer potential due to biological mechanisms suggested in previous research, such as interference with tumor cell growth and metabolism. However, the authors emphasize that the findings are based on only a small number of case reports and cannot establish a definitive cause-and-effect relationship. They suggest that although the outcomes are promising, larger clinical studies and controlled trials are necessary to determine the safety, effectiveness, and appropriate clinical use of fenbendazole in cancer treatment.
PMCID: PMC12215191 PMID: 40605964
